Abstract -Solid lipid nanoparticles (SLNs) comprising complex internal lipids were conjugated with melanotransferrin antibody (MA) to carry anticancer etoposide across the blood-brain barrier (BBB) for managing glioblastoma multiforme (GBM). MA was crosslinked on the surface of etoposide-loaded SLNs (ETP-SLNs) to target human brain-microvascular endothelial cells (HBMECs) and U87MG cells. The experimental evidences showed that an increase in the tripalmitin weight percentage in lipids enhanced the particle size and viability of U87MG cells, however decreased the etoposide loading efficiency, MA conjugation efficiency, and permeability coefficient for etoposide across the BBB. A high level of MA on the particle surface increased the atomic ratio of nitrogen to phosphorus and permeability coefficient for propidium iodide and etoposide across the BBB, however reduced the MA conjugation efficiency, transendothelial electrical resistance, and viability of U87MG cells. Based on immunochemical staining, we found that MA on ETPSLNs triggered the melanotransferrin-mediated transcytosis and promoted the growth-inhibitory efficacy to U87MG cells. MAconjugated ETP-SLNs can be a promising colloidal delivery system for malignant GBM pharmacotherapy.
Introduction
Malignant glioma is a general reason of cancer cause to death, constitutes 78% of malignant brain tumors and 40% of primary brain tumors [1] . In the four categories of glioma, glioblastoma multiforme (GBM) is the highest grade malignancy that median survival of patients for only 12-15 months after therapy [2] . Therefore, GBM medication is important in clinical practice. Several challenges to treat GBM come from the following reasons: aggressive phenotype proliferation and infiltration in the cerebrum, the difficulty in early stage detection, strong resistance to traditional tumor management, and high rate of recurrence [3] . In fact, the modality of current chemotherapy for GBM does not cure cancer and usually induce serious adverse responses [4] . In order to improve the treatment of GBM, the development of adjuvant chemotherapeutics becomes one of unavoidable biomedical issues [5] .
Etoposide (VM-26; VP-16) is a glycosidic derivative from the extract of Mayapple Podophyllum peltatum which belongs to a herbaceous perennial plant in the Berberidaceae family and had been restrained from medicinal utilization by its toxicity for a long time [6] . The application of etoposide to antitumor medication was approved by U.S. Food and Drug Administration through various clinical trials in 1983 [7] . Etoposide binds human type IIA topoisomerase, an enzyme involved in the cleavage of phosphodiester linkage of deoxyribonucleic acid (DNA) through nucleophilic interaction, breaks the DNA strands, and induces apoptosis [8] . However, the blood-brain barrier (BBB) might decrease the drug efficiency for 28 children with therapy of brain tumors in a phase two study on the chemotherapy of etoposide [9] .
Melanotransferrin was first noticed in melanoma cells with an evident localization on the membrane via glycosylphosphatidylinositol anchorage [10, 11] . The membrane melanotransferrin was found to participate in iron transport and metabolism, which was irrelevant to transferrin and transferrin receptor [12, 13] . In addition to iron uptake, melanotransferrin played a novel role in the transcytosis across the BBB [14] .
Lipid nanoparticles have been widely applied to the therapy for glioblastoma. For example, lipid nanoparticles load edelfosine comprising Compritol 888 ATO or Precirol ATO 5 were used to pass through the BBB and inhibit the growth of C6 glioma in mice [15] .
Bevacizumab, an antivascular endothelial growth factor antibody, solid lipid nanoparticles (SLNs) could increase the concentration of bevacizumab to across human umbilical vein endothelial cells for the therapy of glioblastoma [16] .
The aim of this study was to develop etoposide-loaded SLNs (ETP-SLNs) with surface melanotransferrin antibody for GBM treatment. Since melanotransferrin is a membrane-bound protein on endothelial and tumor cells, it may provide an useful pathway in transfer anticancer drug to treat the brain cancer. We use the MA-ETP-SLNs in delivering etoposide across the BBB to inhibit the GBM growth.
Materials and Methods

Preparation of MA-ETP-SLNs
Cacao butter (aka cocoa butter; CB; OCG Cacao, Whitinsville, MA) ,tripalmitin (1,2,3-propanetriyl trihexadecanoate; palmitic triglyceride; TP; Fluka, Buchs, Switzerland), cardiolipin ( , and 2% (w/v) n-butanol (Riedel-de Haen, Seelze, Germany) in ultrapure water (Barnstead, Dubuque, IA). The methanol solution of 10 mL was emulsified with the surfactant solution of 50 mL using a homogenizer (PT 2100, Kinematica AG, Lucerne, Switzerland) at 25000 rpm and 25°C for 10 min. Ultrapure water of 140 mL was added to the emulsified fluid at 400 rpm for 1 h. Thus, the diffusion of methanol in the aqueous phase diluted the content of residual methanol in the microemulsion. Fluorescein isothiocyanate (Sigma-Aldrich) of 50 ppm was mixed in methanol solution for fabricating fluorescent SLNs. The suspension of ETP-SLNs was added to a cellulosic membrane bag (Spectrum Laboratories, Rancho Dominguez, CA) of 50 kDa in a flask of 500 mL, dialyzed against ultrapure water of 200 mL at 150 rpm for 1 h, and strained through a filter with pores of 1 μm. The strained suspension was centrifuged using a centrifuge (AVANTij-25, Beckman Coulter, Palo Alto, CA) at 159000 ×g and 4°C for 10 min. The bottom solids were suspended in ultrapure water with 1% (w/v) D-mannitol (Sigma-Aldrich), frozen in a freezer (Panasonic, Gunma, Japan) at -80°C for 30 min, dried using a lyophilizer (Eyela, Tokyo, Japan) at 266.64-533.29 Pa and -80°C for 24 h, and preserved in a refrigerator at 4°C. After centrifugation, the quantity of free etoposide was evaluated using a high performance liquid chromatograph (HPLC; Jasco, Tokyo, Japan) with a reverse phase BDS Hypersil C-18 column (Thermo Hypersil-Keystone, Bellefonte, PA). In the column, an aqueous acetonitrile (BDH, Poole, England) solution was impelled using two high-pressure pumps (PU-2080 Plus, Jasco). The mobile phase of acetonitrile gradient from 5% (v/v) to 45% (v/v) flowed at a rate of 1 mL/min for 20 min.22 The effluent from HPLC was analyzed using an ultraviolet (UV) 
Particle size and zeta potential of MA-ETP-SLNs
A zetasizer 3000 HSA with a photon correlation spectroscope and a laser Doppler velocimeter (Malvern, Worcestershire, UK) was used to evaluate the cumulant Z-average diameter of MA-ETP-SLNs, D, and zeta potential of MA-a conjugation of MA promoted the interaction between the carriers and cells and enhanced the targeting efficiency. An encapsulation of etoposide in MA-ETP-SLNs could strongly decrease the cytotoxicity to HBMECs and HAs. Therefore, MA-ETP-SLNs might be used for medical treatment.
Conclusion
The particle core of MA-ETP-SLNs were made by various lipid ingredients in particle core and grafting MA on particle surface to transport etoposide, permeate the BBB, and inhibit the growth of GBM. The viability of HBMECs was higher than 89% and that of HAs was higher than 91% means the toxicity of MA-ETP-SLNs to the BBB cells was acceptable. Surface conjugation of MA enhanced the targeting and transcytotic transport of MA-ETP-SLNs to HBMECs and U87MG cells. Therefore, MA-ETPSLNs can be effective nanocarriers in delivering etoposide across the BBB and inhibit the growth of GBM for chemotherapeutic application.
